Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 2/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9680284 | 0.88 | PDE1A (0.32) | PDE1APDE1BPDE1CMAPTKDM4E | |
| SCHEMBL9680313 | 0.88 | PDE1A (0.32) | PDE1APDE1BPDE1CMAPTKDM4E | |
| SCHEMBL9333881 | 0.86 | MAPT (0.35) | PDE1APDE1BPDE1CMAPTKDM4E | |
| SCHEMBL9281981 | 0.85 | MAPT (0.37) | PDE1APDE1BPDE1CMAPTKDM4E | |
| SCHEMBL9246249 | 0.82 | MAPT (0.32) | MAPTKDM4EGAAAPAF1RECQL | |
| SCHEMBL9846230 | 0.77 | BTK (0.41) | MAPTKDM4EGAAAPAF1RECQL | |
| SCHEMBL9846154 | 0.75 | MAPT (0.38) | PDE1APDE1BPDE1CMAPTKDM4E | |
| SCHEMBL9681299 | 0.75 | MAPT (0.35) | MAPTKDM4EGAAAPAF1RECQL | |
| SCHEMBL9846089 | 0.75 | NPSR1 (0.38) | MAPTKDM4EGAAAPAF1RECQL | |
| SCHEMBL9846139 | 0.75 | CYP2C9 (0.37) | PDE1APDE1BPDE1CMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | claimed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |